drugset
drugset / Trial / NCT04478513

A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers

NCT04478513 ↗

Phase 1 Completed 28 enrolled AstraZeneca Parexel · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is a Phase I, open-label, non-randomized, 2-period, fixed-sequence study in healthy volunteers who are either smokers or non-smokers, performed at a single Clinical Unit.

Timeline

Start
2020-07-21
Primary completion
2020-12-23
Completion
2020-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluvoxamine Unknown — Oral
Subject imaradenant Small molecule — Oral

Indications

No indication recorded.